Table 1.
Conventional aggregated study-level data meta-analysis: Pooled incidence of clinical outcomes in chronic hepatitis B patients with or without concomitant fatty liver: (A) hepatocellular carcinoma, (B) cirrhosis, (C) Mortality, and (D) HBsAg seroclearance
| Clinical outcomes | Chronic hepatitis B |
Chronic hepatitis B with fatty liver |
P-value | ||||
|---|---|---|---|---|---|---|---|
| Event | Total | Incidence rate of clinical outcomes (per 1,000 person-years) | Event | Total | Incidence rate of clinical outcomes (per 1,000 person-years) | ||
| HCC (11 studies) | 345 | 9,004 | 6.0, 95% CI: (2.3–9.8) | 173 | 5,010 | 9.4, 95% CI: (4.7–14.1) | 0.27 |
| Cirrhosis (4 studies) | 597 | 4,914 | 8.5, 95% CI: (2.4–14.6) | 202 | 2,287 | 8.3, 95% CI: (7.1–9.4) | 0.93 |
| Mortality (5 studies) | 331 | 6,234 | 5.3, 95% CI: (1.8–8.7) | 99 | 3,032 | 4.6, 95% CI: (2.1–7.0) | 0.75 |
| HBsAg seroclerance (7 studies) | 510 | 6,198 | 27.5, 95% CI: (5.6–49.5) | 410 | 3,264 | 30.5, 95% CI: (12.9–48.1) | 0.84 |
HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; CI, confidence interval.